Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Media ReleaseNew Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patientsNearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1More than 80…
-
Key ReleaseFDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancerAd hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4…
-
Media ReleaseNovartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancerInvasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results…
-
Media ReleaseNovartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD riskPhase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of…
-
Featured NewsNovartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases. xRNA, a core technology platform for Novartis, can target the body’s natural mRNA to modulate the production of proteins that cause disease.
-
Negative impact of the IRA on patient access to innovative treatments
-
StatementNovartis statement on Maximum Fair Price for Entresto
-
Every number has a story – my journey to Novartis as a Refugee
-
Key ReleaseNovartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,…
-
Is Diversity, Equity and Inclusion (DEI) really that important?
-
Media ReleaseNovartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CMLPriority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of…
-
Featured NewsNovartis Financial Results – Q2 2024
Novartis announced the company’s financial results for the second quarter and first half of 2024.
-
Media ReleaseNew Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patientsNearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1More than 80…
-
Key ReleaseFDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancerAd hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4…
-
Media ReleaseNovartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancerInvasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results…
-
Media ReleaseNovartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD riskPhase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of…
-
Key ReleaseNovartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,…
-
Media ReleaseNovartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CMLPriority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of…
-
Key ReleaseNovartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidanceAd hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+…
-
Media ReleaseLatest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative diseaseAddition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease at…
-
Media ReleaseNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CMLPhase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs.…
-
Media ReleaseNovartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticariaPatients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s…
-
Media ReleaseNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolioIn the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (…
-
Media ReleaseNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placeboSecondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical…
-
Key ReleaseFDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancerAd hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4…
-
Key ReleaseNovartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,…
-
Key ReleaseNovartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidanceAd hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+…
-
Key ReleaseNovartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024Annonce événementielle au sens de l’art. 53 RCRésultats du deuxième trimestre (T2)Chiffre d’affaires net en hausse de +11% (tcc1, +9% USD) et du résultat opérationnel core, de +19% (tcc, +17% USD) La…
-
Key ReleaseNovartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehobenAd-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im zweiten Quartal um +11% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +19% (kWk, +17% USD) Das Umsatzwachstum…
-
Key ReleaseNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raisedAd hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD)Key growth drivers continued strong sales momentum including Entresto…
-
Key ReleaseNovartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readoutsAd hoc announcement pursuant to Art. 53 LRFull year (continuing operations2)Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD)Sales growth was mainly driven by…
-
Key ReleaseNovartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase IIIAnnonce événementielle au sens de l’art. 53 RCExercice complet (activités poursuivies2)Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du…
-
Key ReleaseStarkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-ErgebnissenAd-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr (fortzuführende Geschäftsbereiche2)Der Nettoumsatz wuchs um +10% (kWk, +8% USD), und das operative Kernergebnis verbesserte sich um +18% (…
-
Key ReleaseNovartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemiaMEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic…
-
Key ReleaseNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;…
-
Key ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHAd hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement…
-
Featured NewsNovartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases. xRNA, a core technology platform for Novartis, can target the body’s natural mRNA to modulate the production of proteins that cause disease.
-
Featured NewsNovartis Financial Results – Q2 2024
Novartis announced the company’s financial results for the second quarter and first half of 2024.
-
Featured NewsNovartis Financial Results – Q1 2024
Novartis announced the company’s financial results for the first quarter of 2024.
-
Featured NewsNovartis 2023 Financial Results
Novartis announces the company’s fourth quarter and 2023 full year financial results.
-
Featured NewsJ.P. Morgan Healthcare Conference 2024
Latest news and interviews for media and investors
-
Featured NewsOur next era
Novartis poised to expand impact on human health as it begins next era.
-
Featured NewsNovartis Financial Results – Q3 2023
-
Featured NewsNovartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
-
Featured NewsNovartis Financial Results – Q2 2023
Novartis announced the company’s financial results for the second quarter and first half of 2023.
-
Featured NewsNovartis Financial Results – Q1 2023
Novartis announced the company’s financial results for the first quarter of 2023.
-
Featured NewsNovartis 2022 Financial Results
Novartis announces the company’s fourth quarter and 2022 full year financial results.
-
Featured NewsWorld Economic Forum 2023
-
StatementNovartis statement on Maximum Fair Price for Entresto
-
StatementViolence against innocent people runs counter to our work to improve human health
-
StatementNovartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
StatementNovartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
StatementNovartis provides support for Moroccan earthquake victims
-
StatementGT005 (PPY988): Development Program in Geographic Atrophy
-
StatementNovartis statement on filing of Inflation Reduction Act lawsuit
-
StatementNovartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
StatementEuropean Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)
-
StatementCHMP recommends revoking the conditional marketing authorization for Adakveo® (crizanlizumab)
-
StatementNovartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
-
StatementNovartis releases emergency funding of USD 1 million for people in Turkey and Syria, and launches employee donation and volunteering programs
-
Pulse UpdateNovartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
-
Pulse UpdateNovartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
-
Pulse UpdateNovartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
-
Pulse UpdateNovartis appoints Sloan Simpson as Global Head of Investor Relations
-
Pulse UpdateNovartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
-
Pulse UpdateFDA approves Novartis Millburn facility for US commercial production of Pluvicto®
-
Pulse UpdateNovartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch
-
Pulse UpdateNovartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
-
Pulse UpdateNovartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
-
Pulse UpdateFDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Pulse UpdateNovartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Pulse UpdateNovartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
-
Negative impact of the IRA on patient access to innovative treatments
-
Every number has a story – my journey to Novartis as a Refugee
-
Is Diversity, Equity and Inclusion (DEI) really that important?
-
A legacy of blood cancer innovation
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
-
A personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis
-
From black holes to AI driven drug discovery – collaboration wins the day
Dr Bülent Kızıltan, Global Head of AI & Computational Sciences
-
Drug delivery, service delivery, and the future of cancer care
State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.
-
Listening to the CML patient community
Improving the patient experience and removing potential barriers to clinical trial participation
-
How collaboration can enhance your science career
Kumar Veerapen, Senior Expert I Data Science
-
Giving voice to people with a misunderstood disease
Shanelle Gabriel was diagnosed with lupus — a chronic autoimmune disease that mostly affects women of African American and Hispanic descent — while she was at college. Today, as a singer, poet and advocate, she uses her voice to highlight challenges faced by people living with this complex and often misunderstood condition.
Photos: Brent Stirton, Getty Images for Novartis
-
Water project revives rural community in India
Novartis is aiming for water neutrality in our own operations by 2030. In India, we are contributing to this goal through a project near Hyderabad with a nonprofit organization. By tackling both water scarcity and the deprivation it causes, the project has revived the community.
Photos: Bjoern Myhre, Novartis
-
A partnership against epilepsy
Parts of Cameroon have rates of epilepsy that are among the highest in the world. Despite the availability of effective therapies, poverty, a lack of medical resources and superstition about the causes of epilepsy often lead to inadequate treatment and social exclusion for people living with the neurological condition. Novartis is working with a Catholic mission on the ground in a central part of the country to overcome these barriers and improve care.
Photos: Bjoern Myhre, Novartis
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Annual Report 2023
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also contains our operating and financial results, accompanied by audited annual financial statements.